A new technology that will enable patients suffering from Amyotrophic lateral sclerosis (ALS)—also known as Lou Gehrig’s Disease—to communicate via brain monitor, will hold its first clinical trials in Philadelphia, USA. The announcement was made at the BrainTech Israel conference in Tel Aviv (14–15 October).
Philip Low, founder and CEO of NeuroVigil, according to a press release, filed a patent for the new brain monitor—the world’s smallest yet. Low then presented to BrainTech Israel delegates the early evidence of the brain monitor’s success.
Conference attendees watched on video as an ALS patient spell his first word without using his body, by using non-invasive, single-channel, mind-enabled communication. Low has developed other technologies using the monitor to test on patients in various stages of ALS.
“We are starting an entire ALS center at NASA to work with people who have pathologies. We are going to continue the clinical trial in Philadelphia. We are delighted to work with Congressman Fattah and the President [Obama] on the BRAIN initiative,” Low said. “And we are working to create a neurotechnology cluster that will enable us to work together—whether we are in the USA or Israel, or anywhere else in the world.”
